


AMENDMENTS TO THE CLAIMS

Please cancel Claims 1-9 without prejudice and insert therefore new Claims 10-28. This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-9 (canceled)

10. (new) A compound of formula (I):



wherein:

A^1 is phenyl, a six-membered aromatic heterocycle containing one, two or three nitrogen atoms, or a five-membered aromatic heterocycle containing up to four heteroatoms chosen from O, N and S, at most one heteroatom being O or S;

A^1 is unsubstituted or substituted by one, two or three substituents independently chosen from halogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halo C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkoxy, hydroxy, cyano, nitro and amino;

A^2 is phenyl, a six-membered aromatic heterocycle containing one, two or three nitrogen atoms, or a five-membered aromatic heterocycle containing up to four heteroatoms chosen from O, N and S, at most one heteroatom being O or S;

A^2 is unsubstituted or substituted by one, two or three groups independently chosen from halogen, cyano, nitro, amino, C_{1-6} alkylamino, di(C_{1-6} alkyl)amino, C_{1-6} alkyl C_{2-6} alkenyl, C_{2-6} alkynyl, halo C_{1-6} alkyl, hydroxy, C_{1-6} alkoxy, halo C_{1-6} alkyl, thiol, SF_5 , phenyl C_{1-6} alkyl and phenyl;

L is a bond or C_{1-6} alkylene;

R^1 and R^2 independently chosen from hydrogen and C_{1-6} alkyl;

or R¹ and R² may, together, form a methylene or ethylene bridge;

W is halogen, C₁₋₆alkyl, haloC₁₋₆alkyl, C₁₋₆alkoxy or haloC₁₋₆alkoxy;

X is O, S or NR³ where R³ is hydrogen, hydroxy, C₁₋₆alkoxy, C₁₋₆alkyl, cyano, C₃₋₆cycloalkyl, a six-membered saturated heterocycle containing one or two heteroatoms independently chosen from O, N and S, and R³ is, if possible, optionally substituted by C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, halogen, amino, nitro, hydroxy, phenyl, a six-membered aromatic heterocycle containing up to three nitrogen atoms or a five-membered aromatic heterocycle containing up to four heteroatoms chosen from O, N and S, at most one heteroatom being O or S;

or X, together with the atom to which it is attached, and Y, form an unsaturated five-membered ring together with A²;

Y is a bond, C₁₋₄alkylene, NH or NH(CH₂)₁₋₃;

or a pharmaceutically acceptable salt thereof.

11. (new) A compound selected from:

4-fluoro-4-(3-methylpyridin-2-yl)-N-[4-trifluoromethylphenyl]piperidine-1-carboxamide;

4-fluoro-4(pyridin-2-yl)N-[4-trifluoromethylphenyl]piperidine-1-carboxamide;

4-fluoro-4(pyridine-2-yl)N-[4-trifluoromethylbenzyl]piperidine-1-carboxamide;

2-{4-fluoro-1-[4-trifluoromethylbenzoyl]piperidin-4-yl}pyridine;

2-(4-fluoro-1-[(4-trifluoromethylphenyl)acetyl]piperidin-4-yl)pyridine;

2-(4-fluoro-1-{3-[4-trifluoromethylphenyl]propanoyl}piperidin-4-yl)pyridine

4-fluoro-4-(1-methyl-1*H*-imidazol-2-yl)-N-[4-trifluoromethylphenyl]piperidine-1-carboxamide;

4-methoxy-4-pyridin-2-yl-N-[4-trifluoromethylphenyl]piperidine-1-carboxamide;

4-methoxy-4-pyridin-2-yl-N-[4-trifluoromethylbenzyl]piperidine-1-carboxamide;

4-fluoro-N-(4-isopropylphenyl)-4-(3-methylpyridin-2-yl)piperidine-1-carboxamide;

4-fluoro-4-(3-methylpyridin-2-yl)-N-{4-[1,2,2,2-tetrafluoro-1-trifluoromethyllethyl]phenyl}piperidine-1-carboxamide;

N-(4-Tert-butylphenyl)-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-1-carboxamide;

4-fluoro-4-(3-methylpyridin-2-yl)-N-[4-(pentafluoro-λ⁶-sulfanyl)phenyl]piperidine-1-carboxamide;

N-(4-Butylphenyl)-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-1-carboxamide;

N-(4-Benzylphenyl)-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-1-carboxamide;

N-biphenyl-4-yl-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-1-carboxamide;
4-fluoro-4-(3-methylpyridin-2-yl)-*N*-(5-trifluoromethylpyridin-2-yl)piperidine-1-carboxamide;
4-(3-chloropyridin-2-yl)-4-fluoro-*N*-(4-trifluoromethylphenyl)piperidine-1-carboxamide
4-fluoro-4-(3-fluoropyridin-2-yl)-*N*-(4-trifluoromethylphenyl)piperidine-1-carboxamide;
4-fluoro-4-(3-methoxypyridin-2-yl)-*N*-(4-trifluoromethylphenyl)piperidine-1-carboxamide;
4-fluoro-4-(3-methylpyridin-2-yl)-*N*-(4-trifluoromethylphenyl)piperidine-1-carbothioamide;
N-cyano-4-fluoro-4-(3-methylpyridin-2-yl)-*N*-(4-trifluoromethylphenyl)piperidine-1-
carboximidamide;
4-fluoro-4-(3-methylpyridin-2-yl)-*N*-(1-phenylpiperidin-4-yl)-*N*-(4-trifluoromethylphenyl)piperidine-1-
carboximidamide;
4-fluoro-4-phenyl-*N*-(4-trifluoromethylphenyl)piperidine-1-carboxamide;
(+/-)-(syn)-4-fluoro-2-methyl-4-(3-methylpyridin-2-yl)-*N*-(4-trifluoromethylphenyl)piperidine-
1-carboxamide;
4-(fluoromethyl)-4-pyridin-2-yl-*N*-(4-trifluoromethylphenyl)piperidine-1-carboxamide;
syn- and *anti*-3-fluoro-3-pyridin-2-yl-*N*-(4-trifluoromethylphenyl)-8-azabicyclo[3.2.1]octane-8-
carboxamide & 3-fluoro-3-pyridin-2-yl-*N*-(4-trifluoromethylphenyl)-8-azabicyclo[3.2.1]octane-8-
carboxamide;
4-fluoro-4-pyrimidin-2-yl-*N*-(4-trifluoromethylphenyl)piperidine-1-carboxamide;
4-fluoro-4-(3-phenylpropyl)-*N*-(4-trifluoromethylphenyl)piperidine-1-carboxamide;
2-[4-fluoro-4-(3-methylpyridin-2-yl)piperidin-1-yl]-6-trifluoromethyl-1*H*-benzimidazole;
2-(4-fluoro-4-pyridin-2-ylpiperidin-1-yl)-6-(trifluoromethyl)-1*H*-benzimidazole;
4-fluoro-*N*-(4-trifluoromethylphenyl)-4-[3-trifluoromethylpyridin-2-yl)piperidine-1-carboxamide;
4-fluoro-*N*-(4-methylphenyl)-4-(3-methylpyridin-2-yl)piperidine-1-carboxamide;
N-(4-ethylphenyl)-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-1-carboxamide;
N-(4-chlorophenyl)-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-1-carboxamide;
4-fluoro-4-(3-methylpyridin-2-yl)-*N*-(4-trifluoromethoxyphenyl)piperidine-1-carboxamide;
N-(4-cyanophenyl)-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-1-carboxamide;
N-(4-dimethylaminophenyl)-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-1-carboxamide;
and pharmaceutically acceptable salts thereof.

12. (new) A pharmaceutical composition comprising one or more compounds of claim 10 or
11, or pharmaceutically acceptable salts thereof in association with a pharmaceutically acceptable carrier or
excipient.


13. (new) A compound of claim 10 or 11, or a pharmaceutically acceptable salt thereof, for use in treatment of the human or animal body.

14. (new) The use of a compound of claim 10 or 11, or a pharmaceutically acceptable salt thereof for use in the manufacture of a medicament for the treatment or prevention of physiological disorders that may be ameliorated by modulating VR1 activity.

15. (new) The use of a compound of claim 10 or 11, or a pharmaceutically acceptable salt thereof for use in the manufacture of a medicament for the treatment or prevention of a disease or condition in which pain and/or inflammation predominates.


16. (new) The process for the preparation of a compound of claim 10, which comprises:

(A) for compounds wherein Y is NH or NH(CH₂)₁₋₃, reacting a compound of formula (II) with a compound of formula (III):




wherein X¹ is O or S, P is H or a C₁₋₆alkoxycarbonyl group such as tert-butoxycarbonyl and A¹, A², L, R¹, R² and W are as defined in claim 10;

(B) for compounds wherein Y is a bond or C₁₋₄alkylene, reacting a compound of formula (II) with a compound of formula (IV):



wherein both X¹s are O or S, Y is a bond or C₁₋₄alkylene and A² is as defined in claim 1; or

(C) for compounds wherein X, together with the atom to which it is attached, and Y, form an unsaturated five membered ring together with A², reacting a compound of formula (II) with a compound of formula (V):



wherein X, together with the atom to which it is attached and Y, form an unsaturated five membered ring together with A².

17. (new) A method for the treatment or prevention of physiological disorders that may be ameliorated by modulating VR1 activity, which method comprises administration to a patient in need thereof of an effective amount of a compound of claim 10 or a composition comprising a compound of claim 10.

18. (new) A method for the treatment or prevention of a disease or condition in which pain and/or inflammation predominates, which method comprises administration to a patient in need thereof of an effective amount of a compound of claim 10, or a composition comprising a compound of claim 10.